Legend Biotech: An Insight Into Its Manufacturing Capacity Expansion & Major Growth Levers!

Legend Biotech’s recent financial disclosures and strategic updates present a multifaceted view of the company’s performance and outlook. The firm has made significant strides with its CARVYKTI therapy, a CAR-T treatment for multiple myeloma, suggesting a robust growth trajectory influenced by several critical factors. Positively, Legend Biotech is experiencing strong demand for CARVYKTI, with net trade sales reaching approximately $334 million in the fourth quarter of 2024. This figure marks a 110% increase year-over-year, highlighting accelerated growth in the latter half of 2024. The CARTITUDE-4 trial results, which demonstrated a significant survival benefit of CARVYKTI against the standard of care, have been pivotal. An impressive 89% of patients in the trial achieved minimal residual disease negativity compared to 38% in standard care, reinforcing CARVYKTI’s competitive edge. The therapy’s approval for second-line use has also expanded its market reach, now covering 60% of usage in the second through fourth line populations, promoting faster market penetration and growth.